KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Basic) (2016 - 2026)

TherapeuticsMD filings provide 17 years of EPS (Basic) readings, the most recent being $0.01 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 116.67% to $0.01 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.01, a 105.26% increase, with the full-year FY2025 number at -$0.06, up 70.0% from a year prior.
  • EPS (Basic) hit $0.01 in Q1 2026 for TherapeuticsMD, up from -$0.06 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $12.83 in Q2 2022 to a low of -$3.13 in Q3 2022.
  • Median EPS (Basic) over the past 5 years was -$0.06 (2025), compared with a mean of $0.91.
  • Biggest five-year swings in EPS (Basic): soared 8650.0% in 2022 and later crashed 700.0% in 2025.
  • TherapeuticsMD's EPS (Basic) stood at $8.55 in 2022, then crashed by 97.89% to $0.18 in 2023, then crashed by 94.44% to $0.01 in 2024, then plummeted by 700.0% to -$0.06 in 2025, then soared by 116.67% to $0.01 in 2026.
  • The last three reported values for EPS (Basic) were $0.01 (Q1 2026), -$0.06 (Q4 2025), and $0.01 (Q3 2025) per Business Quant data.